Skip to main content
Top
Published in: Breast Cancer 2/2010

01-04-2010 | Case Report

A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II

Authors: Naoki Hino, Yasusi Nakagawa, Youko Ikushima, Mitsuteru Yoshida, Masaru Tsuyuguchi

Published in: Breast Cancer | Issue 2/2010

Login to get access

Abstract

We report the case of a patient who presented with hypoglycemia associated with a giant breast mass and presence of serum high-molecular-weight insulin-like growth factor II (big IGF-II). In July 2005, a 49-year-old woman was admitted because of delirium, transient loss of consciousness, and a giant mass of about 28 cm in diameter on the right breast. She had noticed the mass for more than 2 years, but had refused medical attention at that time. A blood examination indicated hypoglycemia (21 mg/dl) and decreased levels of endogenous insulin. Furthermore, a western blot analysis revealed that big IGF-II (20 kDa) was the predominant serum IGF-II peptide (mature IGF-II is 7.5 kDa). Because we suspected that the big IGF-II was produced by the breast tumor and was likely the cause of the hypoglycemia, a mastectomy was performed. A histological examination determined that the mass was a benign phyllodes tumor. After surgery, the hypoglycemia resolved, and endogenous insulin levels improved. We suspected that the patient had non-islet cell tumor hypoglycemia (NICTH), but the behavioral symptoms of the hypoglycemia caused by NICTH were similar to some mental diseases, which made diagnosis based on the behavior alone difficult. We suggest that co-occurrence of symptoms such as recent appearance of mental disease-like behavior, hypoglycemia, and giant breast tumor may help diagnose NICTH caused by big IGF-II.
Literature
1.
go back to reference Liu F, Baker BK, Powell DR, Hintz RL. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids. J Clin Endocrinol Metab. 1993;76:1095–100.CrossRefPubMed Liu F, Baker BK, Powell DR, Hintz RL. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids. J Clin Endocrinol Metab. 1993;76:1095–100.CrossRefPubMed
2.
go back to reference Hizuka N, Fukuda I, Takano K, Asakawa-Yasumoto K, Okubo Y, Demura H. Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. J Clin Endocrinol Metab. 1998;83:2875–7.CrossRefPubMed Hizuka N, Fukuda I, Takano K, Asakawa-Yasumoto K, Okubo Y, Demura H. Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. J Clin Endocrinol Metab. 1998;83:2875–7.CrossRefPubMed
3.
go back to reference Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991;73:696–702.CrossRefPubMed Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991;73:696–702.CrossRefPubMed
4.
go back to reference Zapf J, Futo E, Peter M, Froesch ER. Can “big” insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest. 1992;90:2574–84.CrossRefPubMed Zapf J, Futo E, Peter M, Froesch ER. Can “big” insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest. 1992;90:2574–84.CrossRefPubMed
5.
go back to reference Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27:246–51.CrossRefPubMed Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27:246–51.CrossRefPubMed
6.
go back to reference Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism. 1993;42:1093–101.CrossRefPubMed Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism. 1993;42:1093–101.CrossRefPubMed
7.
go back to reference Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16:211–6.CrossRefPubMed Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16:211–6.CrossRefPubMed
8.
go back to reference Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319:1434–40.PubMed Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319:1434–40.PubMed
9.
go back to reference Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.CrossRefPubMed Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.CrossRefPubMed
10.
go back to reference Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med. 1981;305:1452–5.PubMedCrossRef Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med. 1981;305:1452–5.PubMedCrossRef
11.
go back to reference Li TC, Reed CE, Stubenbord WT Jr, Ettinghausen S, Peterson CM, Jovanovic L, et al. Surgical cure of hypoglycemia associated with cystosarcoma phyllodes and elevated nonsuppressible insulin-like protein. Am J Med. 1983;74:1080–4.CrossRefPubMed Li TC, Reed CE, Stubenbord WT Jr, Ettinghausen S, Peterson CM, Jovanovic L, et al. Surgical cure of hypoglycemia associated with cystosarcoma phyllodes and elevated nonsuppressible insulin-like protein. Am J Med. 1983;74:1080–4.CrossRefPubMed
12.
go back to reference Kataoka T, Haruta R, Goto T, Sugino K, Asahara T, Dohi K, et al. Malignant phyllodes tumor of the breast with hypoglycemia: report of a case. Jpn J Clin Oncol. 1998;28:276–80.CrossRefPubMed Kataoka T, Haruta R, Goto T, Sugino K, Asahara T, Dohi K, et al. Malignant phyllodes tumor of the breast with hypoglycemia: report of a case. Jpn J Clin Oncol. 1998;28:276–80.CrossRefPubMed
13.
go back to reference Aguiar Bujanda D, Rivero Vera JC, Cabrera Suarez MA, Aguiar Morales J, Christol R, Bohn Sarmiento U, et al. Hypoglycemic coma secondary to big insulin-like growth factor II secretion by a giant phyllodes tumor of the breast. Breast J. 2007;13:189–91.CrossRefPubMed Aguiar Bujanda D, Rivero Vera JC, Cabrera Suarez MA, Aguiar Morales J, Christol R, Bohn Sarmiento U, et al. Hypoglycemic coma secondary to big insulin-like growth factor II secretion by a giant phyllodes tumor of the breast. Breast J. 2007;13:189–91.CrossRefPubMed
Metadata
Title
A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II
Authors
Naoki Hino
Yasusi Nakagawa
Youko Ikushima
Mitsuteru Yoshida
Masaru Tsuyuguchi
Publication date
01-04-2010
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2010
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0094-z

Other articles of this Issue 2/2010

Breast Cancer 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine